JP2017536408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536408A5 JP2017536408A5 JP2017529818A JP2017529818A JP2017536408A5 JP 2017536408 A5 JP2017536408 A5 JP 2017536408A5 JP 2017529818 A JP2017529818 A JP 2017529818A JP 2017529818 A JP2017529818 A JP 2017529818A JP 2017536408 A5 JP2017536408 A5 JP 2017536408A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- prepared
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229950002205 dacomitinib Drugs 0.000 claims 4
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 claims 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 3
- 229960005395 cetuximab Drugs 0.000 claims 3
- 229960001433 erlotinib Drugs 0.000 claims 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 3
- -1 3- bromo-4-chloroanilino Chemical group 0.000 claims 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 229960001686 afatinib Drugs 0.000 claims 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 229950007440 icotinib Drugs 0.000 claims 2
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 claims 2
- 229960004891 lapatinib Drugs 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- HUFOZJXAKZVRNJ-UHFFFAOYSA-N n-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCN(CC2)C(C)=O)=CC=C1NC(N=1)=NC=C(C(F)(F)F)C=1NC1=CC=CC(NC(=O)C=C)=C1 HUFOZJXAKZVRNJ-UHFFFAOYSA-N 0.000 claims 2
- 229950008835 neratinib Drugs 0.000 claims 2
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 229960003278 osimertinib Drugs 0.000 claims 2
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims 2
- 229950009855 rociletinib Drugs 0.000 claims 2
- DFJSJLGUIXFDJP-UHFFFAOYSA-N sapitinib Chemical compound C1CN(CC(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F DFJSJLGUIXFDJP-UHFFFAOYSA-N 0.000 claims 2
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 229920000742 Cotton Polymers 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000028990 Skin injury Diseases 0.000 claims 1
- 229950004272 brigatinib Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229950010203 nimotuzumab Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 238000011255 standard chemotherapy Methods 0.000 claims 1
- 239000003860 topical agent Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087212P | 2014-12-03 | 2014-12-03 | |
| US62/087,212 | 2014-12-03 | ||
| US201562150729P | 2015-04-21 | 2015-04-21 | |
| US62/150,729 | 2015-04-21 | ||
| US201562167849P | 2015-05-28 | 2015-05-28 | |
| US62/167,849 | 2015-05-28 | ||
| US201562187750P | 2015-07-01 | 2015-07-01 | |
| US62/187,750 | 2015-07-01 | ||
| PCT/US2015/063806 WO2016090174A1 (en) | 2014-12-03 | 2015-12-03 | Kinase inhibitor prodrug for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536408A JP2017536408A (ja) | 2017-12-07 |
| JP2017536408A5 true JP2017536408A5 (enExample) | 2019-01-17 |
| JP6769962B2 JP6769962B2 (ja) | 2020-10-14 |
Family
ID=56092487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529818A Active JP6769962B2 (ja) | 2014-12-03 | 2015-12-03 | 癌治療のためのキナーゼ阻害剤プロドラッグ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10507210B2 (enExample) |
| EP (1) | EP3226869A4 (enExample) |
| JP (1) | JP6769962B2 (enExample) |
| CN (2) | CN107427515B (enExample) |
| AU (1) | AU2015358384B2 (enExample) |
| WO (1) | WO2016090174A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10513509B2 (en) | 2016-05-26 | 2019-12-24 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
| KR102323255B1 (ko) | 2017-02-15 | 2021-11-08 | 다이호야쿠힌고교 가부시키가이샤 | 의약 조성물 |
| AU2018329881B2 (en) | 2017-09-08 | 2021-12-02 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent and antitumor effect potentiator |
| CA3074017A1 (en) * | 2017-09-08 | 2019-03-14 | The Regents Of The University Of Colorado, A Body Corporate | Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers |
| US20200261414A1 (en) * | 2017-09-14 | 2020-08-20 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of cancer |
| WO2019125184A1 (en) * | 2017-12-19 | 2019-06-27 | Auckland Uniservices Limited | Use of biomarker in cancer therapy |
| AU2019338185A1 (en) * | 2018-09-04 | 2021-04-22 | Rain Therapeutics Inc. | Compounds, compositions and methods for treating or preventing her-driven cancers |
| WO2020084347A2 (en) * | 2018-10-26 | 2020-04-30 | Auckland Uniservices | Combination of a kinase inhibitor and an immunotherapeutic agent, compositions and methods comprising the same |
| WO2020102304A1 (en) * | 2018-11-13 | 2020-05-22 | Rain Therapeutics Inc. | Combination of a kinase inhibitor and an electrolyte, compositions and methods comprising the same |
| TW202039002A (zh) * | 2018-12-07 | 2020-11-01 | 斯坦福大學托管董事會 | 缺氧標靶組成物及其與一parp抑制劑之組合以及此等的使用方法 |
| EP3931224A4 (en) * | 2019-02-26 | 2023-03-01 | Janssen Biotech, Inc. | COMBINATION TREATMENTS AND PATIENT STRATIFICATION WITH ANTI-EGFR/C-MET BISPECIFIC ANTIBODIES |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| AU8126694A (en) | 1993-10-26 | 1995-05-22 | Affymax Technologies N.V. | Arrays of nucleic acid probes on biological chips |
| US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
| US6228575B1 (en) | 1996-02-08 | 2001-05-08 | Affymetrix, Inc. | Chip-based species identification and phenotypic characterization of microorganisms |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| TWI377944B (en) * | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| US8088782B2 (en) * | 2008-05-13 | 2012-01-03 | Astrazeneca Ab | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A |
| BRPI1011505A2 (pt) | 2009-03-11 | 2016-03-22 | Auckland Uniservices Ltd | formas de pró-drogas de inibidores de quinase e sua aplicação em terapia |
| CN102574846B (zh) * | 2009-09-02 | 2014-12-03 | 奥克兰联合服务有限公司 | 激酶抑制剂、其前药形式及它们在治疗中的用途 |
| US20130288240A1 (en) * | 2010-05-21 | 2013-10-31 | Cell Signaling Technology, Inc. | Alk and ros kinase in cancer |
| US8828391B2 (en) * | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| EP3333161B1 (en) * | 2011-07-27 | 2020-02-19 | Astrazeneca AB | 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer |
| EA031184B1 (ru) * | 2012-11-21 | 2018-11-30 | Янссен Байотек, Инк. | БИСПЕЦИФИЧЕСКИЕ К EGFR/c-Met АНТИТЕЛА |
| BR112015023020A2 (pt) | 2013-03-14 | 2017-07-18 | Pfizer | combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas |
| WO2014169035A1 (en) * | 2013-04-10 | 2014-10-16 | Threshold Pharmaceuticals, Inc. | Predictive and response biomarker for th-302 anti-cancer therapy |
-
2015
- 2015-12-03 EP EP15865257.8A patent/EP3226869A4/en active Pending
- 2015-12-03 JP JP2017529818A patent/JP6769962B2/ja active Active
- 2015-12-03 CN CN201580075139.5A patent/CN107427515B/zh active Active
- 2015-12-03 AU AU2015358384A patent/AU2015358384B2/en active Active
- 2015-12-03 US US15/531,677 patent/US10507210B2/en active Active
- 2015-12-03 CN CN202111320133.3A patent/CN114224894B/zh active Active
- 2015-12-03 WO PCT/US2015/063806 patent/WO2016090174A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536408A5 (enExample) | ||
| IL278423B1 (en) | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment | |
| JP5579715B2 (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| JP2017533912A5 (enExample) | ||
| EP2882454B1 (en) | Combination therapy for the treatment of glioblastoma | |
| JP2019506403A5 (enExample) | ||
| FI3849534T3 (fi) | Yhdistelmähoidot | |
| DK2799070T3 (en) | EFFECTIVE AMPLIFIER FOR ANTITUMUM AGENTS | |
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| JP2019516733A5 (enExample) | ||
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| EA202091514A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR | |
| NZ703940A (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
| MY192354A (en) | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| SG11201806438UA (en) | Fused Pyrazole Derivatives, Preparation Method Thereof, And Use Thereof In Treatment Of Cancers, Inflammation And Immune Diseases | |
| RU2015155283A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| HRP20201819T1 (hr) | Farmaceutski pripravak za liječenje raka koji sadrži laktatnu metalnu sol | |
| PH12021553177A1 (en) | Pharmaceutical composition for treating tumor | |
| MX358501B (es) | Combinación farmacéutica de sinergia para el tratamiento del carcinoma de célula escamosa de cabeza y cuello. | |
| JP2014523421A5 (enExample) | ||
| JP2021505669A5 (enExample) | ||
| Hu et al. | The anti-osteosarcoma cell activity by a mTORC1/2 dual inhibitor RES-529 | |
| RU2010119922A (ru) | Усовершенствованное противоопухолевое лечение |